ArticleFrontiers in immunology2025

Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: a real-world study in China.

Lei Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.